ImmunityBio Inc
IBRX
ISIN null / Valor 110468647
ImmunityBio Inc
UMushroom community rating:
About company
ImmunityBio Inc is a biotechnology company that focuses on developing comprehensive immunotherapy approaches to target various types of cancer and infectious diseases. The company's platforms aim to activate different components of the immune system, such as natural killer cells, T cells, and macrophages, to establish immune memory and trigger an effective anti-tumor immune response. ImmunityBio is currently conducting clinical trials to assess the safety and efficacy of their therapies and personalized vaccine candidates across multiple tumor types. The company has secured significant funding for commercialization and pipeline expansion efforts, with a focus on potential regulatory approval for their bladder cancer treatment N-803. Additionally, ImmunityBio is collaborating with the National Cancer Institute on a study for Lynch syndrome cancer prevention.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (11.10.2025):
ImmunityBio Inc reported its Q2 2025 financial results, demonstrating a substantial 60% increase in revenue compared to Q1 2025, reaching $26.4 million. Year-to-date sales have totaled approximately $43 million, accompanied by a significant 246% growth in ANKTIVA® unit sales since the initiation of the J-code. The company maintains a strong cash position and has secured additional equity financing to support its ongoing operations and clinical programs.
Revenue Growth
In Q2 2025, ImmunityBio Inc achieved $26.4 million in product revenue, marking a 60% increase from Q1 2025. Year-to-date sales have reached approximately $43 million, underscoring the company's strong sales momentum.
ANKTIVA® Unit Growth
The company experienced a 246% increase in ANKTIVA® unit sales volume in the first half of 2025 compared to the second half of 2024, highlighting enhanced market adoption of the product.
Cash Position
As of June 30, 2025, ImmunityBio Inc holds $153.7 million in cash, cash equivalents, and marketable securities. Additionally, the company closed an $80 million equity financing round in July 2025, which includes warrants that could generate up to approximately $96 million in gross proceeds.
Net Loss
For Q2 2025, the net loss attributable to ImmunityBio Inc's common stockholders was $92.555 million. Despite the increase in revenue, the company continues to invest heavily in research and development to drive future growth.
Research and Development
Research and development expenses for Q2 2025 amounted to $52.430 million, reflecting ongoing investments in ImmunityBio's clinical programs and product development initiatives.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1919 M
Market cap (USD)
9,408,512
Daily traded volume (Shares)
2.755 / 2.575
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
